Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

324 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysis.
Canaani J, Beohou E, Labopin M, Ghavamzadeh A, Beelen D, Hamladji RM, Niederwieser D, Volin L, Markiewicz M, Arnold R, Mufti G, Ehninger G, Socié G, Kröger N, Mohty M, Nagler A. Canaani J, et al. Among authors: ghavamzadeh a. J Intern Med. 2019 Apr;285(4):407-418. doi: 10.1111/joim.12854. Epub 2018 Nov 16. J Intern Med. 2019. PMID: 30372796 Free article.
Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMT.
Passweg JR, Labopin M, Cornelissen J, Volin L, Socié G, Huynh A, Tabrizi R, Wu D, Craddock C, Schaap N, Kuball J, Chevallier P, Cahn JY, Blaise D, Ghavamzadeh A, Bilger K, Ciceri F, Schmid C, Giebel S, Nagler A, Mohty M; Acute Leukemia Working Party of the European Blood and Marrow Transplant Group (EBMT). Passweg JR, et al. Among authors: ghavamzadeh a. Bone Marrow Transplant. 2015 Aug;50(8):1063-8. doi: 10.1038/bmt.2015.121. Epub 2015 Jun 1. Bone Marrow Transplant. 2015. PMID: 26030052 Clinical Trial.
What is the outcome in patients with acute leukaemia who survive severe acute graft-versus-host disease?
Ringdén O, Labopin M, Sadeghi B, Mailhol A, Beelen D, Fløisand Y, Ghavamzadeh A, Finke J, Ehninger G, Volin L, Socié G, Kröger N, Stuhler G, Ganser A, Schmid C, Giebel S, Mohty M, Nagler A. Ringdén O, et al. Among authors: ghavamzadeh a. J Intern Med. 2018 Feb;283(2):166-177. doi: 10.1111/joim.12695. Epub 2017 Nov 3. J Intern Med. 2018. PMID: 29027756 Free article.
Allogeneic matched-sibling hematopoietic cell transplantation for AML: comparable outcomes between Eastern Mediterranean (EMBMT) and European (EBMT) centers.
Bazarbachi A, Labopin M, Ghavamzadeh A, Giebel S, Al-Zahrani H, Ladeb S, Leone G, Abdel-Rahman F, Liso V, Hamidieh AA, Rasheed W, Ibrahim A, Alabdulaaly A, Kyrcz-Krzemien S, Arnold R, Kharfan-Dabaja MA, Alimoghaddam K, Aljurf M, Mohty M. Bazarbachi A, et al. Among authors: ghavamzadeh a. Bone Marrow Transplant. 2013 Aug;48(8):1065-9. doi: 10.1038/bmt.2013.1. Epub 2013 Jan 28. Bone Marrow Transplant. 2013. PMID: 23353802
Autologous transplant remains the preferred therapy for relapsed APL in CR2.
Ganzel C, Mathews V, Alimoghaddam K, Ghavamzadeh A, Kuk D, Devlin S, Wang H, Zhang MJ, Weisdorf D, Douer D, Rowe JM, Polge E, Esteve J, Nagler A, Mohty M, Tallman MS. Ganzel C, et al. Among authors: ghavamzadeh a. Bone Marrow Transplant. 2016 Sep;51(9):1180-3. doi: 10.1038/bmt.2016.96. Epub 2016 Apr 18. Bone Marrow Transplant. 2016. PMID: 27088379 Free PMC article.
Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic stem cell transplantation program in countries with limited resources (Part II): Clinical, technical and socio-economic considerations.
Aljurf M, Weisdorf D, Hashmi SK, Nassar A, Gluckman E, Mohty M, Rizzo D, Pasquini M, Hamadani M, Saber W, Hari P, Kharfan-Dabaja M, Majhail N, Gerges U, Hamidieh AA, Hussain F, Elhaddad A, Mahmoud HK, Tbakhi A, Othman TB, Hamladji RM, Bekadja MA, Ahmed P, Bazarbachi A, Adil S, Alkindi S, Ladeb S, Dennison D, Patel M, Lu P, Quessar AE, Okamoto S, Atsuta Y, Alhejazi A, Ayas M, Ahmed SO, Novitzky N, Srivastava A, Seber A, Elsolh H, Ghavamzadeh A, Confer D, Kodera Y, Greinix H, Szer J, Horowitz M, Niederwieser D. Aljurf M, et al. Among authors: ghavamzadeh a. Hematol Oncol Stem Cell Ther. 2020 Mar;13(1):7-16. doi: 10.1016/j.hemonc.2019.08.002. Epub 2019 Aug 20. Hematol Oncol Stem Cell Ther. 2020. PMID: 31449781 Free article.
Challenges and opportunities for HSCT outcome registries: perspective from international HSCT registries experts.
Aljurf M, Rizzo JD, Mohty M, Hussain F, Madrigal A, Pasquini MC, Passweg J, Chaudhri N, Ghavamzadeh A, Solh HE, Atsuta Y, Szer J, Kodera Y, Niederweiser D, Gratwohl A, Horowitz MM. Aljurf M, et al. Among authors: ghavamzadeh a. Bone Marrow Transplant. 2014 Aug;49(8):1016-21. doi: 10.1038/bmt.2014.78. Epub 2014 Apr 28. Bone Marrow Transplant. 2014. PMID: 24777183 Review.
Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients.
Iravani M, Evazi MR, Mousavi SA, Shamshiri AR, Tavakoli M, Ashouri A, Samiee S, Chahardovali B, Alimoghaddam K, Ghaffari SH, Ghavamzadeh A. Iravani M, et al. Among authors: ghavamzadeh a. Bone Marrow Transplant. 2007 Jul;40(2):105-10. doi: 10.1038/sj.bmt.1705685. Epub 2007 Apr 30. Bone Marrow Transplant. 2007. PMID: 17468775
Long-term outcomes of fludarabine, melphalan and antithymocyte globulin as reduced-intensity conditioning regimen for allogeneic hematopoietic stem cell transplantation in children with primary immunodeficiency disorders: a prospective single center study.
Hamidieh AA, Behfar M, Pourpak Z, Faghihi-Kashani S, Fazlollahi MR, Hosseini AS, Movahedi M, Mozafari M, Moin M, Ghavamzadeh A. Hamidieh AA, et al. Among authors: ghavamzadeh a. Bone Marrow Transplant. 2016 Feb;51(2):219-26. doi: 10.1038/bmt.2015.277. Epub 2015 Nov 23. Bone Marrow Transplant. 2016. PMID: 26595073 Clinical Trial.
324 results